Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation

Annals of Internal Medicine

Volumn 126, Issue 7, 1997, Pages 528-531

  Ridker, Paul M ^a   Glynn, Robert J ^a   Miletich, Joseph P ^b   Goldhaber, Samuel Z ^a   Stampfer, Meir J ^a   Hennekens, Charles H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5;

ADULT; AGE; ARTICLE; GENE MUTATION; GENETIC RISK; HIGH RISK POPULATION; HUMAN; INCIDENCE; MALE; NORMAL HUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOEMBOLISM;

EID: 0030978253     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-126-7-199704010-00005     Document Type: Article

References (14)

1. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1993;90:1004-8.
2. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-7.
3. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330:517-22.
4. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993;342:1503-6.
5. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina R, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453-7.
6. Hennekens CH, Buring JE. Epidemiology in Medicine. Boston: Little, Brown; 1987.
7. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332:912-7.
8. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995;92:2800-2.
9. Final report of the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med. 1989;321:129-35.
10. Lindgren BW. Statistical Theory. New York: Macmillan; 1976:130.
11. Grizzle JE, Starmer CF, Koch GG, Analysis of categorical data by linear models. Biometrics. 1969;25:489-504.
12. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151:933-8.
13. Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood. 1994;84:1031-5.
14. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocystinemia, factor V Leiden, and risks of future venous thromboemboiism. Circulation. 1997; [In press].